via University of Wisconsin–Madison
Like the hardiest weed, glioblastoma almost always springs back — usually within months after a patient’s initial brain tumor is surgically removed. That is why survival rates for this cancer are just 25 percent at one year and plummet to 5 percent by the five-year mark.
One of the challenges of treating this disease is that surgeons can’t always remove every bit of tumor or glioma stem cells that might linger in the brain.
“One characteristic of glioblastoma is that the tumor cells are very aggressive, and they will infiltrate the surrounding tissues. So the surgeon can’t clearly feel the boundaries between the tumor and the normal tissue, and you cannot remove as much as possible because all the tissues in the brain are extremely important — you certainly don’t want to remove too much,” explains Quanyin Hu, an assistant professor in the University of Wisconsin–Madison School of Pharmacy’s Pharmaceutical Sciences Division. “So the tumor will come back again, and that sharply decreases the survival rate after treatment.”
But Hu’s Cell-Inspired Personalized Therapeutic (CIPT) Lab has developed a powerful immunity-boosting postoperative treatment that could transform the odds for patients with glioblastoma. Hu and his collaborators published their research on the treatment’s use in mouse models of human glioblastoma this month in the journal Science Translational Medicine.
“It provides hope for preventing glioblastoma relapse,” Hu says. “We prove that it can actually eradicate these glioma stem cells, which can eventually prevent the glioblastoma from coming back. We can significantly improve survival.”
Hu’s lab developed a hydrogel that can be injected into the brain cavity left behind by the excised tumor. The hydrogel delivery method works well because it completely fills the brain cavity, slowly releases the medicine into the surrounding tissue, and promotes the cancer-killing immune response, Hu notes.
“We have a lot of work to do before it can be potentially translated into the clinic, but we feel confident that this is a very promising approach for bringing new hope to patients with glioblastoma so they can recover after surgery.”
Quanyin Hu
The hydrogel is packed with nanoparticles designed to enter and reprogram certain types of immune cells called macrophages. These immune cells normally clean up infectious invaders in the body, but in the tumor environment, they can change into a form that instead suppresses the immune system and promotes cancer growth. And because of the inflammation created by surgery, these rogue macrophages flock to the surgical site, potentially fueling cancer relapse.
“We want to take advantage of these macrophages and turn them from enemy to ally,” Hu says.
To do that, the nanoparticles can engineer the macrophages to target a glycoprotein called CD133, a marker for cancer stem cells. Hu’s team also added an antibody, CD47, that blocks a “don’t-eat-me” signal to promote macrophages to recognize the cancer cells. The preclinical results in mice models show that the hydrogel treatment successfully generated glioma stem cell-specific chimeric antigen receptor (CAR) macrophages — essentially engineering the immune cells on site to target and kill any lingering glioma stem cells.
If effective in humans, the hydrogel treatment could eliminate the need for postsurgical chemotherapy or radiation, reducing toxic side effects while also improving patient outcomes.
Hu’s next step is testing the hydrogel in larger animal models and also monitoring long-term efficacy and toxicity beyond the four- to six-month period he previously studied.
“We have a lot of work to do before it can be potentially translated into the clinic, but we feel confident that this is a very promising approach for bringing new hope to patients with glioblastoma so they can recover after surgery,” Hu says. “We hope we can do our work to be able to advance this technology to the clinic.”
While Hu’s team is initially focused on glioblastoma, the treatment approach could also be applied to other aggressive solid tumors, including breast cancer, he notes. “Our approach is taking advantage of the macrophages in the postsurgical areas and to locally engineer these macrophages,” he says. “In this scenario, we can confidently say that it will apply to the majority of solid tumors with high invasive characteristics.”
Original Article: New injectable gel offers promise for tough-to-treat brain tumors
More from: University of Wisconsin-Madison
The Latest Updates from Bing News
Go deeper with Bing News on:
Immunity-boosting postoperative treatment
- Scientists pinpoint new vaccine adjuvant that promotes potent anti-tumor immunity
Scientists from Trinity College Dublin have made an important breakthrough that offers promise for developing new immune therapies for cancer. They have discovered that a vaccine adjuvant called C100 ...
- Vaccine Improves Immunity via Lymph Node Expansion
A recent paper in Nature Biomedical Engineering, by Dr. David J. Mooney demonstrated how a new vaccine can enhance and maintain lymph node function to boos | Immunology ...
- Hacking the immune system could slow ageing — here’s how
Yet all she had done was to briefly treat them — many weeks earlier — with a drug that corrected the organization of proteins inside a type of stem cell. When technicians who were replicating her ...
- Targeting protein interactions may boost antitumor immunity in breast cancer
A multi-institutional team of investigators has discovered that targeting a specific protein interaction within immunosuppressive breast cancer cells may increase antitumor immune responses in ...
- Cancer immunity gets a boost from one common nutrient, study finds: ‘Intrigue and optimism’
A study of mice published in the journal Science last week found that eating a diet rich in vitamin D changed the gut microbiome in a way that boosted cancer immunity. The micronutrient increased ...
Go deeper with Bing News on:
Hydrogel delivery method
- Nanoparticle researchers develop microfluidic platform for better delivery of gene therapy for lung disease
Drug delivery researchers at Oregon State University have developed a device with the potential to improve gene therapy for patients with inherited lung diseases such as cystic fibrosis.
- After the Afterbirth: A Critical Review of Postpartum Health Relative to Method of Delivery
[4] Discussion of the impact of delivery method on postpartum health is complicated by several factors. First, the vast majority of research in this area was conducted in the United Kingdom ...
- Novel fabrication method creates aligned nanofiber hydrogels for tissue regeneration
A team of chemists and bioengineers at Rice University and the University of Houston have achieved a significant milestone in their work to create a biomaterial that can be used to grow biological ...
- Column: Despite change in delivery method, Aiken Standard is still strives to bring trusted local news
It’s been a week since the Aiken Standard announced it would switch delivery of our printed newspaper to the U.S. Postal Service. The world hasn’t come to an end. In case you missed the news ...
- Innovative peptide-based hydrogel therapy for virus prevention
Vaccines remain the gold standard of protection against dangerous pathogens, but take considerable time and vast resources to develop.